Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

May 14, 2019

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31 to June 4, 2019 in

Read More

May 9, 2019

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict ® test (EPclin)

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of

Read More

April 23, 2019

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of

Read More

April 23, 2019

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

April 17, 2019

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

Creating a Culture of Diversity, Inclusion and Opportunity Is a Top Company Priority SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list

Read More

May 14, 2019

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31 to June 4, 2019 in

Read More

May 9, 2019

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict ® test (EPclin)

Read More

May 1, 2019

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight ® as an benefit

Read More

May 9, 2019

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict ® test (EPclin)

Read More

May 1, 2019

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight ® as an benefit

Read More

April 9, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has

Read More